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An Improved Human Ventricular Cell Model for
Investigation of Cardiac Arrhythmias under
Hyperkalemic Conditions
Abstract
The use of experiments for studying cardiac arrhythmias or the effect of drugs on cardiac electrophysiology
is mostly limited to measurements obtained from electrograms (EGMs, measured on the heart surface) or,
more often, electrocardiograms (ECGs, measured on the body surface). Despite the fact thatmany diagnos-
tic and therapeutical decisions rely only upon interpretation of ECG patterns, the cellular and subcellular
mechanisms underlying pathophysiological ECG changes remain mostly unclear. Among the different ap-
proaches aimed to connect the ECG with its underlying basis, multi-scale computational modeling of the
heart arises as a powerful tool to understand cardiac functioning from the ionic to the whole organ level.
With the increase in computational resources available to the scientiöc community, mathematicalmodeling
and simulation of heart's electrical activity is becoming a fundamental tool to understand cardiac behavior.
In this study several modiöcations were introduced to a recently proposed action potential (AP) cell
model so as to render it suitable for the study of ventricular arrhythmias. These modiöcations were based
on new experimental data and in the results of several cellular arrhythmic risk biomarkers reported in the
literature.
Five stimulation protocols were applied to the original and improvedmodels of isolated cell, and a num-
ber of cellular arrhythmic risk biomarkers were computed. The stimulation protocol included a steady-state
protocol, abrupt changes in cycle length (CL) protocol, S1S2 and dynamic restitution protocols, and concen-
tration rate dependence protocol.
In addition, the behavior of the proposedmodel under hyperkalemic conditions was simulated in a one
dimensional öber by increasing the extracellular [K+], measuring the AP duration (APD), conduction veloc-
ity (CV) and effective refractory period (ERP) after steady-state conditions had been reached.
Our modiöcations led to: a) further improved AP triangulation (78:1ms); b) APD rate adaptation curves
characterized by fast and slow time constants within physiological ranges (10:1 s and 105:9 s); c) maximum
S1S2 restitution slope in accordance with experimental data (SS1S2 = 1:0).
Underhyperkalemia, our results showed thatAPDprogressivelydecreasedwith the level of hyperkalemia,
while ERP increased after a threshold in the extracellular [K+] was reached ([K+]o = 6mM ). Conduction
velocity decreased with hyperkalemia and the conduction was blocked above [K+]o = 10:4mM . Above
[K+]o = 9:8mM , alternans appeared in the APD. These results suggest that the longer ERP values and the
conductionblock above [K+]o = 10:4mM found in the central zoneof acutely ischemic tissue as compared
to the normal zone could create areas of block that could set a substrate for reentrant arrhythmias.
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Mejora de unModelo Celular de Ventrículo
Humano para la Investigación de Arritmias
Cardiacas bajo Condiciones de Hiperpotasemia
Resumen
La utilización de experimentos para el estudio de arritmias cardiacas o el efecto demedicamentos en la elec-
troösiología cardiaca está limitada principalmente a medidas obtenidas de los electrogramas (EGMs, medi-
dos en la superöcie del corazón) o, más habitualmente, electrocardiogramas (ECGs, medidos en la superöce
del cuerpo). A pesar de que muchos diagnósticos y decisiones terapéuticas están fundadas solamente en
la interpretación de los patrones de ECG, los mecanismos celulares y subcelulares subyacentes a cambios
ösiopatológicos en el ECG, continúan no quedando claros en la mayoría de casos. Entre los diferentes acer-
camientos para conectar el ECG con los mecanismos subyacentes, el modelado computacional multiescala
del corazón se plantea como una herramiente potente para entender el funcionamiento cardiaco, desde el
nivel iónico al órgano completo. Con el incremento de los recursos computacionales disponibles para la
comunidad cientíöca, el modelado matemático y la simulación de la actividad eléctrica del corazón se está
convirtiendo en una herramienta fundamental para comprender el comportamiento cardiaco.
En este estudio, varias modiöcaciones fueron introducidas a unmodelo de potencial de acción (AP) pro-
puesto recientemente, para hacerlo apto para el estudio de arritmias ventriculares. Estas modiöcaciones
se basaron en nuevos datos experimentales y en el resultado de varios biomarcadores arrítmicos celulares
presentados en la literatura.
Se aplicaron cinco protocolos de estimulación al modelo origninal y a la versión mejorada para calcular
los diferentes biomarcadores de riesgo arrítmico. Los protocolos de estimulación incluían un protocolo de
estado estático, un protocolo de cambios abruptos en el período de estimulación (CL), los protocolos de
restitución S1S2 y dinámico, y un protocolo de depencencia de las concentraciones a la frecuencia cardiaca.
Además, se simuló el comportamiento del modelo propuesto bajo condiciones de hiperpotasemia en
una öbra unidimensional mediante el incremento de la concentración extracelular deK+, midiendo la du-
racióndelAP (APD), la velocidadde condución (CV) y el período refractario efectivo tras alcanzar condiciones
de estado estable.
Estas modiöcaciones llevaron a: a) mejorar aún más la triangulación del APD (78; 1 ms); b) Caracteri-
zación del APD mediante una constante de tiempo rápida y una lenta dentro del rango ösológico (10; 1 s y
105; 9 s); c)máximapendiente de la curva de restitución S1S2 en concordancia con los datos experimentales
(SS1S2 = 1; 0).
Bajo condiciones hiperpotasémicas, los resulatos mostraron que el APD decrece progresivamente con
el nivel de hiperpotasemia, mientras que el ERP aumenta tras un umbral en la concentración extracelular
deK+ ([K+]o = 6mM ). La CV disminuyó con hiperpotasemia y la conducción se bloqueó por encima de
[K+]o = 10; 4mM . Por encima de [K+]o = 9; 8mM , aparecieron alternantes en el APD. Estos resultados
sugieren que los altos valores de ERP y el bloqueo de conducción sobre [K+]o = 10; 4mM encontrado en
la zona central de tegido isquémico agudo, puede crear un área de bloqueo que sea el substrato para un
arrhitmia reentrante.
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Chapter 1
Introduction
Cardiovascular disease (CVD) is the main cause of death in industrialised countries. More than 2 million
people in the European Union (EU) and nearly 4.5 million people in all Europe die from CVD every year
(European Heart Network 09), a number which is well above that of people dying from cancer, dementia
and HIV/AIDS all together (World Health Organization 09). CVD is thus responsible for 42% of total deaths
in the EU (38% of female, and 45% of male deaths). Spain, despite being one of the countries with the
lowest rate of mortality due to CVD within Europe, is showing a tendency to a worst perspective, with a
2.1% increment per year in the number of such deaths.
1.1 Cardiac Arrhythmias
Among CVD, cardiac arrhythmias represent a common cause of mortality. Cardiac arrhythmias are condi-
tions in which there is a failure in the normal rhythm of the heartbeat. Arrhythmias can be caused either
by an abnormal formation of the electrical impulse, by abnormalities in the conduction of that impulse
throughout the heart, or by both. There are different types of cardiac arrhythmias. The so-called re-entrant
arrhythmias occur when a propagating impulse fails to die out after normal activation of the heart and per-
sists to re-excite other regions that have already recovered excitability. Some arrhythmias of this type are
dangerous and may have fatal consequences.
Frequently occurring re-entrant arrhythmias in the ventricles include monomorphic and polymorphic
ventricular tachycardia (VT) and ventricular öbrillation (VF). Monomorphic VT and polymorphic VT (among
which Torsades de Pointes) both lead to increased ventricular excitation and contraction rates and a de-
crease of cardiac output. In addition, bothmay destabilize into VF. VF leads to a further increase in excitation
rate and a loss of coherence of ventricular contraction, which results in almost zero cardiac output. This will
cause death to occurwithinminutes unless normal sinus rhythm is restored. In Europe sudden cardiac death
(SCD) accounts for over 300,000 deaths per year, of which 75-80% are due to VF. VT and VF thus belong to
the most dangerous cardiac arrhythmias.
1.2 Ischemia
Ischemia is a pathological condition inwhich thedelivery of substrates,mainly oxygen, to themyocardium is
reduced. This causes a progressive deterioration of the electrical activity in the injured region. Three are the
main components of the cellular alterations under ischemia: hyperkalemia, acidosis and hypoxia (Dodama
et al., 1984; Gilmour and Zipes, 1980; Kagiyama et al., 1982; Kishida et al., 1979; Senges et al., 1979; Vleugels
et al., 1980).
Under hyperkalemia, potassium starts to pour out of ischemic myocardial cells causing a depolarization
of themyocardiumat rest, slowing conduction anddecreasingexcitability. Under these conditions, recovery
of excitability is known to outlast repolarization, a phenomenon termed post-repolarization refractoriness.
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Hypoxia causes a reduction in the ATP/ADP ratio than can slow down calcium pumps and exchangers (Tian
and Ingwall, 1196), increasing intracellular sodium and calcium concentrations as well as activating ATP
sensitive potasium channels (IKATP channels) (Carmeliet, 1999). Acidosis reduces the availability of sodium
and calcium channels, reducing excitability and slowing conduction.
These abnormalities cause inhomogeneities of restingpotential anddispersion in recoveryof excitability
in the tissue. In addition, these inhomogeneities set the stage for unidirectional block that can become the
substrate for cardiac arrhythmias.
1.3 NewMethods for Diagnosis and Treatment
Due to the high incidence of CVD in the European population, and among this of cardiac arrhythmias, the
associated cost with it turns out to be huge. It is estimated that CVD costs the EU economy €192,000million
a year, and €7,000 million a year to the Spanish Government, thus becoming the main cause of disease
burden (European Heart Network 09). Based on these numbers it is clear that industrialised countries, and
in particular Europe and Spain, need to face the challenge of appropriatelymanaging prevention, diagnosis
and treatment of cardiac diseases but at affordable cost. It is in this context where computational tools may
provide relevant capabilities to improve quality and efficiency of healthcare services.
Mathematicalmodeling and simulation of heart’s electrical activity (so-called cardiac electrophysiology)
and signal processing of bioelectrical signals provide an ideal frameworkwhere to join the information from
clinical and experimental studies with the understanding of the mechanisms underlying them so as to pro-
duce tools able to test different hypothesis and predict potential abnormalities in heart's behavior. In a
relatively near future it is not unlikely that those tools might even become to start being used in clinical
practice as complementary instruments to help in the prevention of cardiac diseases and the improvement
of their diagnosis and therapy.
1.4 Computational Modeling and Simulation
At present, clinical data is mostly limited to measurements obtained from electrograms (EGMs, measured
on the heart surface) or, more often, electrocardiograms (ECGs, measured on the body surface). The main
reason behind the extensive use of the ECG signal in the clinics can be found in the fact that, in addition
to being a non-invasive procedure, is simple and of low-cost. Despite the fact that many diagnostic and
therapeutical decisions rely only upon interpretation of ECG patterns, the cellular and subcellular mecha-
nisms underlying pathophysiological ECG changes remainmostly unclear. Among the different approaches
aimed to connect the ECGwith its underlying basis, multi-scale computational modeling of the heart arises
as a powerful tool to understand cardiac functioning from the ionic to the whole organ level.
There are a number of important reasons that support the use of cardiacmodels to explain ECG-derived
outcomes. First, modeling represents an alternative to experimental investigation, which is pretty much
limited by ethical considerations, particularly when dealing with human hearts. Animal experimentation
on other species, such as guinea pigs, rabbits or pigs, turns out to be more feasible, but corresponding
results are not always easily transferable to humans, due to differences in key aspects such as heart size,
heart rate, or duration and shape of the action potential (AP, representative of the electrical activity of a cell)
(ten Tusscher et al., 2004). Another advantage of modeling is that it offers the possibility to test hypothesis
or investigate conditions that are not easily reproducible in experiments, as it is the case with the study of
three-dimensional phenomena, where experimental recording techniques offer limited possibilities due to
poor spatial resolution, poor depth resolution, or applicability only to wedge preparations (ten Tusscher,
2004). Finally, computer models are of great importance in öelds such as drug testing, where the use of
simulations can help to detect adverse properties of compounds before their commercialization, and thus
reduce the cost of bringing a new drug to the market.
Computationalmodeling of the heart has experienced agreat development during the last öve decades.
In 1960 Noble formulated the örst electrophysiological model for cardiacmyocytes (Noble, 1960), and since
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then more complex models of cellular electrical activity have been proposed for different species and re-
gions of the heart (Courtemanche et al., 1998; Grandi et al., 2010; Luo and Rudy, 1991, 1994; Maleckar et al.,
2009; Noble et al., 1998; ten Tusscher and Panölov, 2006). Additional modeling of the communication be-
tweenneighbouring cellsmakes it possible to extend those cellmodels and convert them into tissueor even
whole organ models. The electrical properties of the myocardium are generally described by the bidomain
equations, a set of coupled parabolic and elliptic partial differential equations (PDEs) that represents the
tissue as two separate, distinct continua - one intracellular and the other extracellular. The intracellular and
the extracellular media are connected via the cell membrane, and thus the two PDEs are coupled at each
point in space through a set of non-linear ordinary differential equations (ODEs), which describe the ionic
transport across the cell membrane. In some cases, the monodomain representation of cardiac activity is
used, which involves solving a single parabolic PDE, by assuming either that the extracellular potentials are
negligible, or that the anisotropy ratios are equal in the intracellular and theextracellular domains (Bernabeu
et al., 2009).
1.5 Human Ventricular Cell Models
In the last years some mathematical models of electrical and ionic homeostasis in human ventricular my-
ocytes have been proposed. One of the most extensively used models is the one proposed by ten Tusscher
and Panölov (ten Tusscher and Panölov, 2006) (TP06), which is an improved version of the model described
in (ten Tusscher et al., 2004) (TNNP04), where the calcium dynamics, the slow delayed rectiöer current (IKs)
and the L-type calcium current (ICaL) were reformulated. The major advantage of the TP06 model is that it
accurately reproduces the behavior of the AP duration restitution curve (see Section 2 for more information
about this). Other relevant model for human ventricular cells was described in the paper by Iyer et al. (Iyer
et al., 2004). In thismodel themain ionic currents aredescribedusingMarkovian chains, the reason forwhich
the model becomes very complex, having more than 60 state variables. Recently, a new model of human
ventricular AP has been proposed by Grandi et al. (Grandi et al., 2010) (GPB), which improves the response
to frequency changes and has a better performance against current blocks with respect to the TP06model.
1.6 This Work
Despite the fact that the human ventricular APmodels currently available in the literature are able to repro-
duce certain electrophysiological properties, they fail in representing other relevant aspects, as will be later
described. In order to obtain a model suitable for the study of cardiac arrhythmias, in this study we have
worked on building a new human ventricular APmodel based on the analysis of well-known arrhythmic risk
biomarkers. For that, we have used the GPB model as a starting point, and we have modiöed it by account-
ing for recent experimental measurements of potassium currents (Fink et al., 2008) and by introducing fast
and slow voltage-dependent inactivation gates for the L-type calcium current (ten Tusscher and Panölov,
2006).
All the modiöcations were made with the aim of improving the model performance on several arrhyth-
mic risk biomarkers (see Chapter 2). The proposedmodel, herein denoted by CRLP, has been tested against
the GPB and TP06models by applying four stimulation protocols and computing twelve cellular arrhythmic
risk biomarkers following the methodology proposed in (Romero et al., 2009). The results show that the
introduced modiöcations have brought most biomarkers into the physiological range, and considerably
improved others with respect to the GPB and TP06 models of AP.
The proposed model has also been tested under hyperkalemic conditions to evaluate the feasibility of
using this model for studying the acute regional ischemic heart.
This document is structured in four chapters, each one with the following contents:
 Chapter 2 introduces the importance of using arhythmic risk biomarkers to develop models and de-
scribes each of the arrhythmic risk biomarkers used in the evaluation of the model and how they are
computed.
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 Chapter 3 establishes the basis for the development of the new CRLP model and describes the modi-
öcations introduced to the GPBmodel to render it more suitable for the study of cardiac arrhythmias.
 Chapter 4 describes the simulation tests conducted to evaluate model's performance and presents
the corresponding results.
 Chapter 5 presents the discussion and the conclusions of the study.
In addition, other contents can be found in the appendices to the main document:
 Appendix A: Description of the CRLP human ventricular cell model.
 Appendix B: Contributions of the study to international conferences.
 Appendix C: Compilation of the acronyms used in the document.
UniversidadZaragoza
Chapter 2
Biomarkers of arrhythmic risk
Arrhythmic risk biomakers are commonly used to predict drug cardioxicity in the development process of a
new pharmacological compound. In a study developed by Romero et al. (Romero et al., 2009) an evaluation
of how the principal ionic currents of a human ventricular cell model inøuence different biomarkers was
presented. Despite these evidences, the traditional way of developing a cellular model is based on isolated
measurements on cells (i.e., individual ionic currents or intracellular concentrations). The exclusive use of
current measurements leads to many uncertainties, as it only provides information about the behavior of
each current, but not about the contribution of each current to the global cellular behavior.
The main goal of this study is to propose a new methodology for the development of ionic cell models
that joins the two types of approaches described above for model development. Speciöcally, in this study
biomarkers of arrhythmic risk were used to drive the modiöcations of the model. While the formulation of
individual currents was based on speciöc measurements, model parameters were adjusted based on differ-
ent biomarkers that must remain within a physiological range. This allowed the proposedmodel to provide
results in better concordance with experimental data.
In the following sections, the main cellular arrhythmic risk biomarkers are presented, and the protocols
used to measured them are described.
2.1 Selected Biomarkers
In this study, a number of arrhythmic risk biomarkers proposed in the literature were selected to be used for
model evaluation purposes, following the methodology described in (Romero et al., 2009):
 APD: The AP duration (APD) is considered the main preclinical biomarker of drug cardiotoxicity be-
casuse of its link to longQT syndrome (Hondeghem et al., 2001; Volders et al., 2000). Unless otherwise
speciöed, APD is used to denote AP duration at 90% repolarization.
 Triangulation: This biomarker represents the shape of the end of the AP, calculated as the difference
between the APD at 50% and 90% of the repolarization (Figure 2.1.a). Low triangulation values are
indicative of square APs, while high values indicate triangular APs. It has been proposed as a predictor
of serious proarrhythmia in (Hondeghem et al., 2001).
 Systolic and diastolic [Ca2+]i levels : The calcium dynamics at different frequencies has been re-
ported as a risk biomarker in (Bers andDespa, 2006; Pieske et al., 1999). These biomarkers evaluate the
diastolic (calcium level at rest) and the systolic (calcium level at peak) values for different frequencies
(Figure 2.1.b).
 Time constants of the APD adaptation to abrupt changes in cycle length (CL): The adaptation to
abrupt changes in CL was proposed as an arrhythmic risk biomarker in (Pueyo et al., 2004). In (Pueyo
et al., 2010) the APD adaptation to abrupt changes in CL was ötted by two exponentials with time
constants fast and slow (Figure 2.1.c). These time constants were reported as cellular arrhythmic
risk biomarkers.
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Figure 2.1. Graphical description of the biomarkers of arrhythmic risk used in this study: a) steady-state AP
properties; b) steady-state [Ca2+]i; c) APD adaptation to abrupt changes in CL (from 1,000 ms to 600 ms
and again to 1,000 ms); d) APDR curve computed using the S1S2 protocol; e) APDR curve computed using
the dynamic procol; f ) rate dependence of systolic concentrations.
 Maximum slope of the APDR curves: The maximum slope of the APD restitution (APDR) curve
(Figures 2.1.d-e) was suggested as a risk biomarker in (Nolasco and Dahlen, 1968; Weiss et al., 2006).
The APDR curve describes the relationship between the APD and the diastolic interval (DI), and in this
study it has been evaluated using the S1S2 and the dynamic protocols (see Section 2.2).
 RatedependenceofNa+ andCa2+ concentrations: The importanceof intracellular sodiumcon-
centration ([Na+]i) and intracellular calcium concentration ([Ca2+]i) in arrhythmogenesis has been
reported in (Levi et al., 1997; Murphy and Eisner, 2009).
2.2 Stimulation Protocols for Biomarkers Eval-
uation
Five stimulation protocols were applied to evaluate the risk bimoarkers presented in section 2.1. In all the
cases, cells were stimulated with square transmembrane current pulses of 1-ms duration and twice the dis-
astolic threshold at CL of 1,000 ms:
 Steady-state protocol: This protocol consists in the application of a train of 3,000 pulses to stabilize
the cellular model. Simulations were carried out using two different CL values (1,000 and 2,000 ms).
The evaluated biomarkers were: AP at 1 Hz, Triangulation at 1 Hz, Systolic [Ca2+]i at 0.5 and 1 Hz, and
Diastolic [Ca2+]i at 0.5 and 1 Hz.
 Abrupt changes in cycle length protocol: The cell was stimulated with a CL of 1,000 ms for 8 min-
utes, then with a CL of 600 ms for additional 8 minutes and önally with a CL of 1,000 ms during 8
minutes (Figure 2.1). The dynamics of the örst abrupt CL changewere ötted by two exponentials with
time constants fast and slow . The APD adaptation dynamics after the second abrupt CL change pro-
vided very similar results to those obtained for the örst CL change, in accordance with (Pueyo et al.,
2010; Romero et al., 2009), and are not reported.
 S1S2 protocol: This protocol consists of a train of 10 square current pulses at a CL of 1,000 ms fol-
lowed by an extra stimulus applied at coupling intervals (CI) ranging from 1,000 to 250 ms. The S1S2
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restitution curvewas obtained by ploting the APD corresponding to the extrastimulus versus the pre-
vious diastolic interval (DI) for each of the values (Figure 2.1.d).
 Dynamic protocol: This protocol consists of 100 cycles applied at different CL values ranging from
1,000 to 50 ms. In this study the APDR curve was obtained by ploting the steady-state APD (corre-
sponding to the 100th stimulus of each CL) versus the corresponding steady-state DI (Figure 2.1.e).
 Rate dependence protocol: The systolic values of both [Na+]i and [Ca2+]i concentrations were
measured at different frequencies (0.25, 0.5, 1, 1.5, 2, 2.5 and 3 Hz) and normalized to the level of the
minimum frequency. For each frequency, the cell was stimulated during 10 minutes to reach steady-
state. The maximum normalized concentration value was computed and used as a biomarker (Figure
2.1.f).
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Chapter 3
Model Development
3.1 Modelingofelectricalactivity incell andtis-
sue
In general, the cell membrane is modeled as a capacitor connected in parallel with variable resistances
and batteries representing the different ionic currents and pumps (Figure 3.1). Mathematically it can be
expressed as:
Cm
dVm
dt =   (Iion   Istim) ;
where Vm represents the membrane potential, t denotes time, Iion is the sum of all transmembrane ionic
currents, Istim is the externally applied stimulus current, and Cm is the cell capacitance per unit surface
area.
In the case of simulating electrical propagation in a 1-D öber, a parabolic reaction diffusion equation is
used to describe the electrical activity of coupled cells:
Cm
@Vm
@t
=   (Iion   Istim) + @
@x


@V
@x

;
where  is the conductivity of the tissue and x is the coordinate along the öber.
3.2 The available GPBModel
In the original GPB model, the total Iion current is given by:
Iion = INatot + ICltot + ICatot + IKtot ;
where each of the individual currents denote the current generated by the pass of the ions of sodium, chlo-
rine, calcium and potassium, respectively, through the cell membrane.
29
30 Jesús Carro Fernández
Figure3.1. Anelectric circuit representationof amembranepatch. In this diagram,VNa,VK , andVL represent
the absolute values of the respective electromotive forces and the signs indicate their directions when the
extracellular medium has a normal composition (highNa+ andCl+, and lowK+ concentrations). Graphic
from (Plonsey and Malmivuo, 1995).
3.2.1 Sodium current
The sodium current is divided into two components, which correspond to the parts of themembranewhere
the current is generated: subsarcolemmal or junctional zone. Both of them are composed by the same
subcurrents:
INatotjunc = INajunc + INaBkjunc + 3  Incxjunc + 3  INa,Kjunc + ICaNajunc
INatotsl = INasl + INaBksl + 3  Incxsl + 3  INa,Ksl + ICaNasl
INatot = INatotjunc + INatotsl
where INa is the fast sodium current, INaBk is the background sodium current, Incx is the current of the
sodium-calcium exchanger, INa,K is the current of the sodium-potassium pump, and ICaNa is the sodium
current through the L-type calcium channels.
3.2.2 Chlorine current
The chlorine current, which is not present in the TP06 model, is described in the GPB model by:
ICltot = IClCa + IClBk
where IClCa is the calcium-activated chlorine current, and IClBk is the background chlorine current.
3.2.3 Calcium current
The calcium current, as the sodium current, has two components, junctional and subsarcolemal:
ICatotjunc = ICajunc + ICaBkjunc + IpCajunc   2  Incxjunc
ICatotsl = ICasl + ICaBksl + IpCasl   2  Incxsl
ICatot = ICatotjunc + ICatotsl
where ICa is the calcium current through the L-type calcium channels, ICaBk is the background calcium cur-
rent, IpCa is the sarcolemmal calciumpumpcurrent, and Incx is the current of the sodium-calciumexchanger.
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3.2.4 Potassium Current
Finally, the potassium current is deöned as follows:
IKtot = Ito + IKr + IKs + IK1   2  INa,K + ICaK + IKp
where Ito is the transient outward potassium current, IKr is the rapidly activating potassium current, IKs is
the slowly activating potassium current, IK1 is the inward rectiöer potassium current, INa,K is the current of
the sodium-potassium pump, ICaK is the potassium current through the L-type calcium channels, and IKp is
the plateau potassium current.
3.3 The Proposed CRLPModel
Taking the GPBmodel as a starting point andwith the aim of obtaining a bettermodel to investigate cardiac
arrhythmias, two ionic currents (ICaL and IK1) were reformulated and some model parameters of the GPB
model were redeöned. In the following sections, all these modiöcations are presented as well as the data
and criteria they were based on.
3.3.1 L-Type Calcium Current (ICaL)
In order to obtain an APD adaptation response to abrupt changes in CL in better concordance with experi-
mental data, the L-type calciumcurrentwas reformulated. The voltage-dependent inactivationgate f of the
GPB model was replaced with the product of a fast, f , and a slow, f2, inactivation gates, as in (ten Tusscher
and Panölov, 2006). The new equations for the L-type current in our CRLP model are as follows:
ICajunc = FjuncCaL  ICaj  d  f  f2 

1  fCaBj

ICasl = FslCaL  ICasl  d  f  f2 

1  fCaBsl

ICaNajunc = FjuncCaL  INaj  d  f  f2 

1  fCaBj

ICaNasl = FslCaL  INasl  d  f  f2 

1  fCaBsl

ICaK =
IK  d  f  f2 

FjuncCaL 

1  fCaBj

+ FslCaL 

1  fCaBsl

Additionally, the value of the opening rate f2 , associated with f2, was modiöed based on available
experimental data (Figures 3.2a-b). Figure 3.2.a depicts f and f2 along with experimental data (Benitah
et al., 1992; Beuckelmann et al., 1991; Li et al., 1999;Mewes andRavens, 1994; Sun et al., 1997). The equations
that describe f and f2, including the new deönition of f2 , are the following:
fss =
1
1 + e
Vm+20
7
f = 1102:5  e (
Vm+27
15 )
2
f =
200
1 + e
13 Vm
10
f =
180
1 + e
Vm+30
10
+ 20
f = f + f + f
df
dt =
fss   f
f
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f2ss =
0:67
1 + e
Vm+35
7
+ 0:33
f2 = 300  e
 (Vm+25)2
170
f2 =
31
1 + e
25 Vm
10
f2 =
16
1 + e
Vm+30
10
f2 = f2 + f2 + f2
df2
dt =
f2ss   f2
f2
Additionalmodiöcations to the L-type calcium current include redeönition of the time constant d of the
activation gate d, which was replaced with the description given in (ten Tusscher and Panölov, 2006). The
equations for the activation gate d of the L-type calcium current in the CRLP model are:
dss =
1
1 + e
 (Vm+5)
6
d =
1:4
1 + e
 35 Vm
13
+ 0:25
d =
1:4
1 + e
Vm+5
5
d =
1
1 + e
50 Vm
20
d = d  d + d
dd
dt =
dss   d
d
The calcium-dependent inactivation gates (fCaBj and fCaBsl ) deönitions were taken as in the GPBmodel:
dfCaBj
dt = 1:7  Caj 

1  fCaBj

  11:9  10 3  fCaBj
dfCaBsl
dt = 1:7  Casl 

1  fCaBsl

  11:9  10 3  fCaBsl
The relative permeabilities of the L-type calcium channels were adjusted to:
pCa = 1:9887  10 4 cm/s
pK = 5:4675  10 8 cm/s
pNa = 3:0375  10 9 cm/s
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Figure 3.2. Current characteristics in simulations and experiments: a) ICaL inactivation time constants as
function of Vm; b) ICaL current density versus voltage; c) maximum IK1 versus voltage and experimental
data. [K+]i = 138mM and [K+]o = 4mM ; d) Detail of c. Blue dots and markers: experimental data.
ICaj =
pCa  Vm  Frdy  FoRT 
 
Caj  e2VmFoRT   Cao

e2VmFoRT   1
ICasl =
pCa  Vm  Frdy  FoRT 
 
Casl  e2VmFoRT   Cao

e2VmFoRT   1
INaj =
pNa  Vm  Frdy  FoRT 
 
Naj  eVmFoRT  Nao

eVmFoRT   1
INasl =
pNa  Vm  Frdy  FoRT 
 
Nasl  eVmFoRT  Nao

eVmFoRT   1
IK =
pK  Vm  Frdy  FoRT 
 
Ki  eVmFoRT  Ko

eVmFoRT   1
The results obtained with the new deönition of the ICaL current were compared against experimental
data and against the results derived from the original deönition of ICaL in the GPB model. These results are
presented in Figure 3.2.b. Experimental data is from (Li et al., 1999;Magyar et al., 2000; Pelzmannet al., 1998).
3.3.2 Inward Rectiöer K Current (IK1)
The IK1 current was readjusted based on experimental data from (Fink et al., 2008). In the CRLP model, the
IK1 current is formulated as follows:
aK1 =
4:094
1:0 + e0:1217(Vm EK 49:934)
bK1 =
15:720  e0:0674(Vm EK 3:257) + e0:0618(Vm EK 594:31)
1:0 + e 0:1629(Vm EK+14:207)
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K1ss =
aK1
aK1 + bK1
IK1 = 0:5715 
r
[K+]o
5:4
K1ss  (Vm   EK)
where [K+]o denotes the extracellularK+ concentration, andEK is theK+ reversal potential. Figure 3.2.c
shows the modiöed IK1 compared against the experimental data from (Fink et al., 2008) and IK1 from the
GPB model. Note that Figure 3.2.c is a detail of Figure 3.2.c.
3.3.3 Na/K Pump Current (INa,K)
In order to improve the APD adaptation response to abrupt changes in CL, maximal INa,K conductance was
reduced by 45% with respect to the GPB model.
3.3.4 [K+]i andGNa
A more physiological value for [K+]i of 138mM was used in our model. Considering this value for [K+]i
and in order to get physiological values for the maximal upstroke velocity in tissue, dV /dt, the maximum
conductance of the sodium current,GNa, was reduced to 18:86mS/F .
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Chapter 4
Results
4.1 Conducted Simulations
Our proposed CRLP model was tested against the arrhythmic risk biomarkers described in chapter 2 and
the results were compared against those obtained using the previously published TP06 and GPB human
ventricular cell models. Also, in order to test the model in the same situations described in (Grandi et al.,
2010), current blocks were simulated as reported in (Grandi et al., 2010). Finally, the behavior of the model
under hyperkalemic conditionswas simulated in aone-dimensional öber, and conduction velocity (CV), APD
and effective refractory period (ERP) were measured.
Cells were stimulatedwith square transmembrane current pulses twice the diastolic threshold and 1-ms
duration. Forward Euler integration with a time step t = 0:002ms was used to integrate the system of
differential equations governing the cellular electrical behavior. The Rush and Larsen integration scheme
(Rush and Larsen, 1978) was used to integrate the Hodgkin-Huxley type equations for the gating variables
of the various time-dependent currents (m, h, and j for INa; xtof , xtos , ytof and ytos for Ito; xkr for IKr ; xks
for IKs and d, f and f2 for ICaL).
In the hyperkalemia study, a 4 cm long multicellular öber was used. For the simulations, the operator
splitting techique was implemented for solving the reaction-diffusion equation that describes the conduc-
tion along a cable. The same integration scheme used in isolated cells was used in this case. Implicit Euler
with a time stept = 0:002ms andamesh sizex = 0:1mmwasused to integrate theparabolic equation.
To obtain a maximum planar CV of 74 cm/s (Taggart et al., 2000), a cellular conduction of 0:0013 cm2/ms
was required. Five positions within the öber were selected for further analysis in each simulation. These
positions were located at 1.5, 1.75, 2, 2.25 and 2.5 from the stimulation end of the cable. The APD and the
CV were computed as their mean values over these positions.
4.2 Results for Control Conditions
4.2.1 Biomarkers of arrhythmic risk
Table 4.1 shows the computedbiomarkers for themodiöedCRLPmodel. Results are compared against those
obtained with previous models (TP06 and GPB) and against a variety of physiological data described in
(Beuckelmann et al., 1992; Drouin et al., 1995; Franz et al., 1988; Li et al., 1998, 1999; Nash et al., 2006; Pieske
et al., 1999, 2002; Schmidt et al., 1998).
These results indicate that the GPB model performs better than the TP06 model with respect to the
following biomarkers: triangulation, systolic and diastolic [Ca2+]i at 0.5 Hz and rate dependence of steady-
state [Na+]i and [Ca2+]i. However, according to other analyzed biomarkers, the GPBmodel renders worse
results than the TP06 model. Speciöcally, in (Franz et al., 1988) two phases of APD rate adaptation were
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Biomarker TP06 GPB CRLP Physiolo.
APD90 301.2 285.0 305.6 271-366
Triangulation 28.4 51.5 78 44-112
Sys [Ca2+]i 1 Hz 0.886 0.383 0.602 1.59-2.01
Sys [Ca2+]i 0.5 Hz 0.199 0.345 0.523 0.71-1.68
Dia [Ca2+]i 1 HZ 0.104 0.089 0.097 0.20-0.33
Dia [Ca2+]i 0.5 Hz 0.068 0.085 0.091 0.14-0.32
SmaxS1S2 1.3 0.2 1.0 0.79-4.25
SmaxDYN 1.0 1.1 0.9 ---
fast 13.3 --- 10.2 ---
slow 124.8 56.3 105.6 70-110
Max. sys. [Ca2+]i 1157 178 147 130-170
Max. sys. [Na+]i 217 132 134 145
Table 4.1. Biomarkers of arrhythmic risk for the TP06, GPB and CRLP human models. Green color indicates
within physiological range. Blue color indicates out of physiological range but better than previousmodels.
Red color indicates out of physiological range.
reported: a örst phase with a short time constant and a second phase with a longer time constant. The APD
rate response in the GPB model does not present this örst phase. Also, the S1S2 restitution curves of the
TP06 model (Figure 4.1.c) are in better agreement with experimental data.
For the CRLPmodel, most of the twelve analyzed biomarkers arewithin physiological range or otherwise
closer to the physiological range as compared to GPB and TP06 models, except for systolic and diastolic
[Ca2+]i levels at 1 Hz, where TP06 outperforms CRLP.
4.2.2 Blocking Currents
We have also studied the behavior of the model under total and partial block of potassium currents, com-
paring the results against those reported in (Jost et al., 2008) from experiments in human ventricle:
 IKs: To simulate the effect of 1 M of HMR-1556, IKs was completely blocked.
 IKr : To simulate the effect of 50 nM of dofetilide, IKr was completely blocked.
 IK1: To simulate the effect of 10 M ofBaCl2, IK1 was reduced by 50%.
Table 4.2 summarizes the effect of current block on the differentmodels. Results are given as percentage
of variation of the APD value in control conditions. In those cases where more than one current is blocked,
the variation refers to the APD obtained when the örst current is blocked. Experimental values have been
taken from (Jost et al., 2008).
In Figure 4.2 the efects of the different blocks for the original and the modiöed models are represented.
4.3 Results for Hyperkalemic Conditions
For the simulationofhyperkalemia a1-dimensional öberwasused, asdescribed in section4.1. Hyperkalemic
conditions were simulated by increasing the extracellular K+ concentration from 4.0 mM to 15 mM (de-
pending on the degree of simulated hyperkalemia).
The stimulation protocol consisted of a train of ten basic stimulations (S1) with a cyclic length of 1,000
ms, followed by an extrasystole stimulus (S2) delivered at different times taken in 0.1 millisecond steps in
order to determine ERP. CV and APD were measured after the last S1 stimulus.
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Figure 4.1. Biomarkers of arrhythmic risk from TP06, GPB and CRLP models: a) AP for CL = 1000 ms; b)
APD rate adaptation to abrupt changes in CL (From 1000 ms to 600 ms); c) S1S2 restitution protocol curve;
d) Dynamic restitution protocol curve; e) rate dependence of steady-state [Na+]i; f ) Rate dependence of
steady-state [Ca2+]i
Current Ref. TT GPB CRLP Exper.
IKr 0% Control 74.9 0.7 0.6 < 2.8
IKr 0% Control 15.9 18.6 14.1 444
IKs 0% IKr B. --- 1.4 0.8 9IKr 0%
IK1 50% Control 3.6 11.5 14.6 4.81.5
IKr 0% IKr B. 8.9 15.6 21.1 33IK1 50%
Table 4.2. Percentages of variation in the APD caused by blocking different currents. Green color indicates
within physiological range. Blue color indicates out of physiological range but better than previousmodels.
Red color indicate out of physiological range.
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GPB Model
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CRLP Model
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Figure 4.2. Blocking currents for the GPB and CRLP models: a) Effect of completely blocking IKr and IKs
currents in the GPB model, b) Effect of completely blocking IKr and partialy blocking IK1 in the GPB model,
b) Effect of completely blocking IKr and IKs currents in the CRLP model, b) Effect of completely blocking IKr
and partially blocking IK1 in the CRLP model.
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Figure4.3. Behavior of themodel under hyperkalemic conditions in 1-D öber: a) conduction velocity versus
[K+]o; b) example of alternans for [K+]o = 10:0mM , each color represents a different position in the öber;
c) dependence of ERP and APD with the [K+]o.
The basic stimuli consisted of rectangular pulses of 3 ms duration and 1.5 times the diastolic threshold.
This threshold was determined as follows. For a given [K+]o value, themodel was örst stabilized until when
the product of the gates h  j reached 99% of the steady-state value hss  jss. Once the model had reached
steady-state conditions, an stimulation current was applied at the left end of the cable. Diastolic threshold
wasdeönedas theminimumstimulation current required inorder for an actionpotential topropagate along
the cable.
4.3.1 Conduction Velocity
Figure 4.3.a shows CV obtained for different values of [K+]o. In our proposed CRLPmodel, as in TP06, there
is no supernormal conduction (Shaw and Rudy, 1997) (Kagiyama et al., 1982). Above 10.4 mM there is no
conduction and over 9.8 mM alternans appeared (Figure 4.3.b).
4.3.2 Action Potential Duration and Effective Refractory Period
Figure 4.3.c shows APD and ERP measurements for different values of [K+]o. APD decreases when the ex-
tracellularK+ concentration increases. For high [K+] values, the APD curve is divided into two branches,
which is explained by the ocurrence of alternans at those high concentrations.
The ERP has three phases. In the örst one, ERP decreases with APD. After this, ERP begins to increase
(the excitability of the cells decreases due to the increase in [K+]o). Finally, the last phase is caused by the
ocurrence of alternans. Depending on whether the beat that is measured is an odd or an even beat, ERP
takes one or another value.
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Chapter 5
Discussion and conclusions
In this study a new human ventricular cell model has been developed, which is suitable for investigation of
cardiac arrhythmias. Taking the recently proposedGPBmodel as a starting point, severalmodiöcations have
been introduced by accounting for recent experimental measurements of potassium currents, and by refor-
mulating the L-type calcium current so as to introduce fast and slow voltage-dependent inactivation. All the
modiöcations have been made with the aim of maintaining the advantages that the GPB model presents
over previous models, such as the TP06 model, while improving the performance on other electrophysio-
logical aspects. The novelty of this study is that the development of our proposed CRLP model is not only
based on new data from experiments of ionic currents. More importantly, the development is also based
on the results of several arrhythmic risk biomarkers reported in the literature.
For the proposed CRLPmodel, the introduction of fast and slow ICaL inactivation has led to amore physi-
ological rate adaptation response as compared to the original GPBmodel. The othermodiöcations have ren-
dered most biomarkers to be within the physiological range or otherwise closer to the physiological range
as compared to the GPB and TP06models, except for systolic and diastolic [Ca2+]i levels at 1 Hzwhere TP06
outperforms CRLP. These modiöcations, however, have altered the behavior of the model against current
blocks minimally, thus providing results in very good agreement with available experimental data.
The results of the analysis conducted in this studypoints out the importance that calciumdynamics have
over different biomarkers. This suggests the need for continuing with the development of more reliable
calcium dynamic models that allow improving the performance of whole cell AP models.
The hyperkalemia simulations showed that APD progressively decreasedwith the level of hyperkalemia,
while ERP increased after a threshold in the extracellular [K+] was reached ([K+]o = 6mM ). Conduction
velocity decreased with hyperkalemia and the conduction was blocked above [K+]o = 10:4 mM . Addi-
tionally, alternans appeared in the APD above [K+]o = 9:8mM . These results suggest that the longer ERP
values and the conduction blocking above [K+]o = 10:4mM found in the central zone of acutely ischemic
tissue as compared to the normal zone could create areas of block that could set the stage for reentrant
arrhythmias.
Future develpments of the model will include a complete ischemic model with ATP sensitive potassium
current (IKATP) and simulations of acidosis. The simulations with the model will be made, not only in a 1-D
öber but in 2-D tissue and in a realistic human ventricular geometry.
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Clinical Practice

Clinical Practice
The clinical practice of the studywas conducted atHospital Clínico de Valencia. It was divided into two parts.
The örst part was carried out in collaboration with the group directed by Dr. Ricardo Ruiz Granell in the
Cardiostimulation Unit. The second part was conducted in the research group led by Dr. Francisco Javier
Chorro about the investigation of different pathologies using rabbit hearts.
In the örst part of the clinical practice with the group of Dr. Ricardo Ruiz, several interventions were wit-
nessed. Some cardioversions were performed by team doctors, where different types of arrhythmias were
terminated by delivering a synchronized shock. Likewise, different checks and follow-ups of pacemakers
and deöbrillators were witnessed.
Also, an intervention in a patient with history of chronic ischemic arrhythmia took place during the days
of the internship. In that intervention an ablation of the part of the heart causing reentrant circuits was
performed. For this, örst of all, a 3D map of the inside of the heart and its electrical activity was measured.
An arrhythmia was induced with an extra-stimulus test to check its focus and, önally, all the identiöed zone
was burned in order to prevent the spread of late fronts.
During the days of the clinical practice, different conversations on the applicability of the investigation
with computational models took place between the student and the doctors. In this conversations the doc-
tors proposed the application of our model to the investigation of arrhythmias caused by genetic diseases
like Brugada syndrome, where some channels present a pathological behavior and are common in the clin-
ical routine. Other pathologies like arrhythmias caused by acute ichemia were very rare to önd in the clinic
because usually the patient does not survive to reach the hospital and in case it happens, the procedure is
clear, to deliver an electroshock.
During the second part of the clinical practice with the group led by Dr. Francisco Javier Chorro, some
experiments in rabbit hearts were witnessed. This group is currently working in the study of the differences
between the heart response in rabbits trained and not trained. Likewise, they are working on comparing
the electrophysiology of the heart in control conditions and when it is subjected to stretch. In this studies
they are using an increasing stimulation frequency to generate arrhythmias and the extra-stimulus test to
study CV and ERP. With a sensor they perform an electrical mapping in the surface of the heart and they
process the measures to create activation maps. For all these experiments they use a Langendorff system
that allows them to mantain the heart alive after having been extracted from the body. With this clinical
practice it was posible to see a real application of the same procedures used in the simulations conducted
in this study.
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Appendices

Appendix A
Human Ventricular Cell Model
A.1 Model Parameters
A.1.1 Physical Constants
Name Value Units
R 8314 J/(mol K)
Frdy 96485 C/mol
T 310 K
FoRT Frdy/(R  T ) mV  1
Cmem 1:381  10 10 F
A.1.2 Enviromental Parameters
Name Value Units
Lengthcell 100  10 5 dm
Radiuscell 10:25  10 5 dm
Vcell  Radius2cell  Lengthcell L
Vmyo 0:65  Vcell L
Vsr 0:035  Vcell L
Vsl 0:02  Vcell L
Vjunc 5:39  10 4  Vcell L
JCajunc,sl 8:2413  10 13 L/ms
JCasl,myo 3:7243  10 12 L/ms
JNajunc,sl 1:8313  10 14 L/ms
JNasl,myo 1:6386  10 12 L/ms
A.1.3 Fractional Currents
Name Value Units
Fjunc 0:11 [ ]
Fsl 1  Fjunc [ ]
FjuncCaL 0:9 [ ]
FslCaL 1  FjuncCaL [ ]
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A.1.4 Ion Concentrations
Name Value Units
Ki 138 mM
Ko 5:4 mM
Cli 15 mM
Clo 150 mM
Cao 1:8 mM
Mgi 1 mM
Nao 140 mM
A.1.5 Sodium Transport
Name Value Units
GNa 18:86 mS/F
GNaB 0:597  10 3 mS/F
INaK 0:99 pA/pF
KmKo 1:5 mM
KmNaip 11 mM
A.1.6 Potassium Currents
Name Value Units
pNaK 1:833  10 2 [ ]
GK1 5:7153  10 1 mS/F
GKp 2  10 3 mS/F
GKr 3:5  10 2 mS/F
GKsjunc 3:5  10 3 mS/F
GKssl 3:5  10 3 mS/F
Gtof ;EPI 1:144  10 1 mS/F
Gtos;EPI 1:56  10 2 mS/F
Gtof ;ENDO 1:404  10 3 mS/F
Gtos;ENDO 3:7596  10 2 mS/F
A.1.7 Chlorine currents
Name Value Units
GClCa 0:054813 mS/F
GClB 9  10 3 mS/F
KdClCa 100  10 3 mM
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A.1.8 Calcium Transport
Name Value Units
pCa 1:9887  10 4 L/(F ms)
pK 5:4675  10 8 L/(F ms)
pNa 3:0375  10 9 L/(F ms)
INCX 4:5 pA/pF
KmCai 3:59  10 3 mM
KmCao 1:3 mM
KmNai 12:29 mM
KmNao 87:5 mM
ksat 0:32 [ ]
nu 0:27 [ ]
Kdact 0:15  10 3 mM
IPMCA 0:0673 pA/pF
KmpCa 0:5  10 3 mM
GCaB 5:513  10 4 mS/F
A.1.9 SR Calcium Fluxes
Name Value Units
VmaxSRCaP 5:3114  10 3 mM/ms
ec50SR 0:45 mM
hillSRCaP 1:787 [ ]
kiCa 0:5 mM
 1 mS 1
kim 0:005 mS
 1
koCa 10 mM
 2 ms 1
kom 0:06 mS
 1
ks 25 mS 1
Kmf 0:246  10 3 mM
Kmr 1:7 mM
MaxSR 15 [ ]
MinSR 1 [ ]
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A.1.10 Buffering
Name Value Units
BmaxCaM 24  10 3 mM
BmaxSR 17:1  10 3 mM
BmaxTnChigh 140  10 3 mM
BmaxTnClow 70  10 3 mM
Bmaxmyosin 140  10 3 mM
BmaxNaj 7:561 mM
BmaxNasl 1:65 mM
BmaxSLlowsl
37:4  10 3  Vmyo/Vsl mM
BmaxSLlowj
4:6  10 4  Vmyo/Vjunc mM
BmaxSLhighsl
13:4  10 3  Vmyo/Vsl mM
BmaxSLhighj
1:65  10 4  Vmyo/Vjunc mM
Bmaxcsqn 140  10 3  Vmyo/Vsr mM
koffcsqn 65 mS
 1
koffCaM 238  10 3 mS 1
koffSR 60  10 3 mS 1
koffTnChCa
0:032  10 3 mS 1
koffTnChMg
3:33  10 3 mS 1
koffTnCl 19:6  10 3 mS 1
koffmyoCa 0:46  10 3 mS 1
koffmyoMg 0:057  10 3 mS 1
koffslh 30  10 3 mS 1
koffsll 1:3 mS
 1
koffNa 1  10 3 mS 1
koncsqn 100 mM
 1 mS 1
konCaM 34 mM
 1 mS 1
konSR 100 mM
 1 mS 1
konTnChCa
2:37 mM 1 mS 1
konTnChMg
3  10 3 mM 1 mS 1
konTnCl 32:7 mM
 1 mS 1
konmyoCa 13:8 mM
 1 mS 1
konmyoMg 0:0157 mM
 1 mS 1
konslh 100 mM
 1 mS 1
konsll 100 mM
 1 mS 1
konNa 0:1  10 3 mM 1 mS 1
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A.2 Model Equations
A.2.1 Nerst Potentials
ENajunc =
1
FoRT
 ln Nao
Naj
ENasl =
1
FoRT
 ln Nao
Nasl
EKs =
1
FoRT
 ln Ko + pNaK Nao
Ki + pNaK Nai
EK =
1
FoRT
 ln Ko
Ki
ECajunc =
1
2  FoRT  ln
Cao
Caj
ECasl =
1
2  FoRT  ln
Cao
Casl
ECl =
1
FoRT
 ln Cli
Clo
A.2.2 INa:Fast Sodium Current
mss =
1
1 + e
 (56:86+Vm)
9:03
2
m = 0:1292  e (
Vm+45:79
15:54 )
2
+ 0:06487  e (Vm 4:82351:12 )2
dm
dt =
mss  m
m
ah =

0 if Vm   40
0:057  e (Vm+80)6:8 otherwise
bh =
(
5:9231
1+e
 (Vm+10:66)
11:1
if Vm   40
2:7  e0:079Vm + 3:1  105  e0:3485Vm otherwise
h =
1
ah + bh
hss =
1
1 + e
Vm+71:55
7:43
2
dh
dt =
hss   h
h
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aj =
(
0 if Vm   40
( 2:5428104e0:2444Vm 6:94810 6e 0:04391Vm)(Vm+37:78)
1+e0:311(Vm+79:23) otherwise
bj =
(
0:6e0:057Vm
1+e 0:1(Vm+32) if Vm   40
0:02424e 0:01052Vm
1+e 0:1378(Vm+40:14) otherwise
j =
1
aj + bj
jss =
1
1 + e
Vm+71:55
7:43
2
dj
dt =
jss   j
j
INajunc = Fjunc GNa m3  h  j 
 
Vm   ENajunc

INasl = Fsl GNa m3  h  j  (Vm   ENasl)
INa = INajunc + INasl
A.2.3 INaBk: Background Sodium Current
INaBkjunc = Fjunc GNaB 
 
Vm   ENajunc

INaBksl = Fsl GNaB  (Vm   ENasl)
INaBk = INaBkjunc + INaBksl
A.2.4 INa,K: Na-K Pump Current
 =
e
Nao
67:3   1
7
fNaK =
1
1 + 0:1245  e 0:1VmFoRT + 0:0365    e VmFoRT
INa,Kjunc =
Fjunc  INaK  fNaK Ko
1 +

KmNaip
Naj
4
 (Ko +KmKo)
INa,Ksl =
Fsl  INaK  fNaK Ko
1 +

KmNaip
Nasl
4
 (Ko +KmKo)
INa,K = INa,Kjunc + INa,Ksl
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A.2.5 IKr: Rapidly Activating Potassium Current
xrss =
1
1 + e
 (Vm+10)
5
xr =
3300
1 + e
 22 Vm
9



1 + e
Vm+11
9
 + 230
1 + e
Vm+40
20
dxKr
dt =
xrss   xKr
xr
rKr =
1
1 + e
Vm+74
24
IKr = GKr 
r
Ko
5:4
 xKr  rKr  (Vm   EK)
A.2.6 IKs: Slowly Activating Potassium Current
xsss =
1
1 + e
 (Vm+3:8)
14:25
xs =
990:1
1 + e
 (Vm+2:436)
14:12
dxKs
dt =
xsss   xKs
xs
IKsjunc = Fjunc GKsjunc  x2Ks  (Vm   EKs)
IKssl = Fsl GKssl  x2Ks  (Vm   EKs)
IKs = IKsjunc + IKssl
A.2.7 IKp: Plateau Potassium Current
kpKp =
1
1 + e7:488 
Vm
5:98
IKp = GKp  kpKp  (Vm   EK)
A.2.8 Ito: Transient Outward Potassium Current
xtoss =
1
1 + e
 (Vm 19)
13
xtos =
9
1 + e
Vm+3
15
+ 0:5
dxtos
dt =
xtoss   xtos
xtos
ytoss =
1
1 + e
Vm+19:5
5
ytos =
800
1 + e
Vm+60
10
+ 30
dytos
dt =
ytoss   ytos
ytos
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xtof = 8:5  e (
Vm+45
50 )
2
+ 0:5
dxtof
dt =
xtoss   xtof
xtof
ytof = 85  e
 (Vm+40)2
220 + 7
dytof
dt =
ytoss   ytof
ytof
Itos = Gtos  xtos  ytos  (Vm   EK)
Itof = Gtof  xtof  ytof  (Vm   EK)
Ito = Itos + Itof
A.2.9 IK1:Inward Rectiöer Potassium Current
aK1 =
4:0938
1 + e0:12165(Vm EK 49:9344)
bK1 =
15:7197  e0:06739(Vm EK 3:2571) + e0:06175(Vm EK 594:31)
1 + e 0:16285(Vm EK+14:2067)
K1ss =
aK1
aK1 + bK1
IK1 = GK1 
r
Ko
5:4
K1ss  (Vm   EK)
A.2.10 IClCa: Calcium-Activated Chlorine Current
IClCajunc =
Fjunc GClCa
1 + KdClCaCaj
 (Vm   ECl)
IClCasl =
Fsl GClCa
1 + KdClCaCasl
 (Vm   ECl)
IClCa = IClCajunc + IClCasl
A.2.11 IClBk: Background Chlorine Current
IClBk = GClB  (Vm   ECl)
A.2.12 ICaL: L-type Calcium Current
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Voltage-Dependent Activation Gate
dss =
1
1 + e
 (Vm+5)
6
d =
1:4
1 + e
 35 Vm
13
+ 0:25
d =
1:4
1 + e
Vm+5
5
d =
1
1 + e
50 Vm
20
d = d  d + d
dd
dt =
dss   d
d
Voltage-Dependent Inactivation Gates
fss =
1
1 + e
Vm+20
7
f = 1102:5  e (
Vm+27
15 )
2
f =
200
1 + e
13 Vm
10
f =
180
1 + e
Vm+30
10
+ 20
f = f + f + f
df
dt =
fss   f
f
f2ss =
0:67
1 + e
Vm+35
7
+ 0:33
f2 = 300  e
 (Vm+25)2
170
f2 =
31
1 + e
25 Vm
10
f2 =
16
1 + e
Vm+30
10
f2 = f2 + f2 + f2
df2
dt =
f2ss   f2
f2
Calcium-Dependent Inactivation Gates
dfCaBj
dt = 1:7  Caj 

1  fCaBj

  11:9  10 3  fCaBj
dfCaBsl
dt = 1:7  Casl 

1  fCaBsl

  11:9  10 3  fCaBsl
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Currents
ICaj =
pCa  Vm  Frdy  FoRT 
 
Caj  e2VmFoRT   Cao

e2VmFoRT   1
ICasl =
pCa  Vm  Frdy  FoRT 
 
Casl  e2VmFoRT   Cao

e2VmFoRT   1
INaj =
pNa  Vm  Frdy  FoRT 
 
Naj  eVmFoRT  Nao

eVmFoRT   1
INasl =
pNa  Vm  Frdy  FoRT 
 
Nasl  eVmFoRT  Nao

eVmFoRT   1
IK =
pK  Vm  Frdy  FoRT 
 
Ki  eVmFoRT  Ko

eVmFoRT   1
ICajunc = FjuncCaL  ICaj  d  f  f2 

1  fCaBj

ICasl = FslCaL  ICasl  d  f  f2 

1  fCaBsl

ICaNajunc = FjuncCaL  INaj  d  f  f2 

1  fCaBj

ICaNasl = FslCaL  INasl  d  f  f2 

1  fCaBsl

ICaK =
IK  d  f  f2 

FjuncCaL 

1  fCaBj

+ FslCaL 

1  fCaBsl

ICa = ICajunc + ICasl
ICaNa = ICaNajunc + ICaNasl
ICaL = ICa + ICaK + ICaNa
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A.2.13 Incx: Na-Ca Exchanger Current
Kajunc =
1
1 +

Kdact
Caj
2
Kasl =
1
1 +

Kdact
Casl
2
s1junc = e
nuVmFoRT Na3j  Cao
s1sl = e
nuVmFoRT Na3sl  Cao
s2junc = e
(nu 1)VmFoRT Na3o  Caj
s2sl = e
(nu 1)VmFoRT Na3o  Casl
s3junc = KmCai Na3o 
 
1 +

Naj
KmNai
3!
+Km3Nao  Caj 

1 +
Caj
KmCai

+KmCao Na3j +Na3j  Cao +Na3o  Caj
s3sl = KmCai Na3o 
 
1 +

Nasl
KmNai
3!
+Km3Nao  Casl 

1 +
Casl
KmCai

+KmCao Na3sl +Na3sl  Cao +Na3o  Casl
Incxjunc =
Fjunc  INCX Kajunc  (s1junc   s2junc)
s3junc 
 
1 + ksat  e(nu 1)VmFoRT

Incxsl =
Fsl  INCX Kasl  (s1sl   s2sl)
s3sl 
 
1 + ksat  e(nu 1)VmFoRT

Incx = Incxjunc + Incxsl
A.2.14 IpCa: Sarcolemmal Calcium Pump Current
IpCajunc =
Fjunc  IPMCA  Ca1:6j
Km1:6pCa + Ca
1:6
j
IpCasl =
Fsl  IPMCA  Ca1:6sl
Km1:6pCa + Ca
1:6
sl
IpCa = IpCajunc + IpCasl
A.2.15 ICaBk: Background Calcium Current
ICaBkjunc = Fjunc GCaB 
 
Vm   ECajunc

ICaBksl = Fsl GCaB  (Vm   ECasl)
ICaBk = ICaBkjunc + ICaBksl
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A.2.16 SRFluxes: CalciumRelease, SRCalciumPump,SRCalciumLeak
kCaSR = MaxSR  
MaxSR  MinSR
1 +

ec50SR
CaSR
2:5
koSRCa =
koCa
kCaSR
kiSRCa = kiCa  kCaSR
RI = 1 RyRr  RyRo  RyRi
dRyRr
dt = kim RI   kiSRCa  Caj RyRr  
 
koSRCa  Ca2j RyRr   kom RyRo

dRyRo
dt = koSRCa  Ca
2
j RyRr   kom RyRo   (kiSRCa  Caj RyRo   kim RyRi)
dRyRi
dt = kiSRCa  Caj RyRo   kim RyRi  
 
kom RyRi   koSRCa  Ca2j RI

JSRCarel = ks RyRo  (CaSR   Caj)
JserCa =
VmaxSRCaP 

Cai
Kmf
hillSRCaP   CaSRKmr hillSRCaP
1 +

Cai
Kmf
hillSRCaP
+

CaSR
Kmr
hillSRCaP
JSRleak = 5:348  10 6  (CaSR   Caj)
A.2.17 Ion Homeostasis
Sodium Buffers
dNaBj
dt = konNa Naj 

BmaxNaj  NaBj

  koffNa NaBj
dNaBsl
dt = konNa Nasl 

BmaxNasl  NaBsl

  koffNa NaBsl
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Cytosolic Calcium Buffers
dTnCl
dt = konTnCl  Cai 

BmaxTnClow   TnCl

  koffTnCl  TnCl
dTnChc
dt = konTnChCa  Cai 

BmaxTnChigh   TnChc   TnChm

  koffTnChCa  TnChc
dTnChm
dt = konTnChMg Mgi 

BmaxTnChigh   TnChc   TnChm

  koffTnChMg  TnChm
dCaM
dt = konCaM  Cai  (BmaxCaM   CaM)  koffCaM  CaM
dMyoc
dt = konmyoCa  Cai 
 
Bmaxmyosin  Myoc  Myom
  koffmyoCa Myoc
dMyom
dt = konmyoMg Mgi 
 
Bmaxmyosin  Myoc  Myom
  koffmyoMg Myom
dSRB
dt = konSR  Cai  (BmaxSR   SRB)  koffSR  SRB
JCaBcytosol =
dTnCl
dt +
dTnChc
dt +
dTnChm
dt +
dCaM
dt +
dMyoc
dt +
dMyom
dt +
dSRB
dt
Junctional and SL Calcium Buffers
dSLLj
dt = konsll  Caj 

BmaxSLlowj
  SLLj

  koffsll  SLLj
dSLLsl
dt = konsll  Casl 

BmaxSLlowsl
  SLLsl

  koffsll  SLLsl
dSLHj
dt = konslh  Caj 

BmaxSLhighj
  SLHj

  koffslh  SLHj
dSLHsl
dt = konslh  Casl 

BmaxSLhighsl
  SLHsl

  koffslh  SLHsl
JCaBjunction =
dSLLj
dt +
dSLHj
dt
JCaBsk =
dSLLsl
dt +
dSLHsl
dt
Sodium Concentrations
dNaj
dt =
 INatotjunc  Cmem
Vjunc  Frdy +
JNajunc,sl
Vjunc
 (Nasl  Naj) 
dNaBj
dt
dNasl
dt =
 INatotsl  Cmem
Vsl  Frdy +
JNajunc,sl
Vsl
 (Naj  Nasl) +
JNasl,myo
Vsl
 (Nai  Nasl)  dNaBsldt
dNai
dt =
JNasl,myo
Vmyo
 (Nasl  Nai)
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Calcium Concentrations
dCsqnb
dt = koncsqn  CaSR 
 
Bmaxcsqn   Csqnb
  koffcsqn  Csqnb
dCaj
dt =
 ICatotjunc  Cmem
Vjunc  2  Frdy +
JCajunc,sl
Vjunc
 (Casl   Caj)  JCaBjunction +
JSRCarel  Vsr
Vjunc
+
JSRleak  Vmyo
Vjunc
dCasl
dt =
 ICatotsl  Cmem
Vsl  2  Frdy +
JCajunc,sl
Vsl
 (Caj   Casl) +
JCasl,myo
Vsl
 (Cai   Casl)  JCaBsk
dCai
dt =
 JserCa  Vsr
Vmyo
  JCaBcytosol +
JCasl,myo
Vmyo
 (Casl   Cai)
dCaSR
dt = JserCa  

JSRleak  Vmyo
Vsr
+ JSRCarel

  dCsqnbdt
A.2.18 Membrane Potential
ICatotjunc = ICajunc + ICaBkjunc + IpCajunc   2  Incxjunc
ICatotsl = ICasl + ICaBksl + IpCasl   2  Incxsl
ICatot = ICatotjunc + ICatotsl
IKtot = Ito + IKr + IKs + IK1   2  INa,K + ICaK + IKp
INatotjunc = INajunc + INaBkjunc + 3  Incxjunc + 3  INa,Kjunc + ICaNajunc
INatotsl = INasl + INaBksl + 3  Incxsl + 3  INa,Ksl + ICaNasl
INatot = INatotjunc + INatotsl
ICltot = IClCa + IClBk
Iion = INatot + ICltot + ICatot + IKtot
dVm
dt =   (Iion   Istim)
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A.3 Initial Conditions
Name EPI ENDO Units
CaSR 6:093596  10 1 6:138856  10 1 mM
Cai 9:658067  10 5 9:719632  10 5 mM
Caj 2:038197  10 4 2:048633  10 4 mM
Casl 1:184305  10 4 1:188246  10 4 mM
Csqnb 1:258048 1:262853 mM
CaM 3:267494  10 4 3:288063  10 4 mM
Myoc 2:520383  10 3 2:522168  10 3 mM
Myom 1:369529  10 1 1:369514  10 1 mM
SRB 2:373753  10 3 2:38683  10 3 mM
TnChc 1:225914  10 1 1:225802  10 1 mM
TnChm 8:12201  10 3 8:128604  10 3 mM
TnCl 9:757237  10 3 9:811535  10 3 mM
h 7:13497  10 1 7:126555  10 1 [ ]
j 7:128671  10 1 7:119893  10 1 [ ]
m 2:163678  10 3 2:176608  10 3 [ ]
SLHj 8:053908  10 2 8:078504  10 2 mM
SLHsl 1:235381  10 1 1:238366  10 1 mM
SLLj 8:563314  10 3 8:606485  10 3 mM
SLLsl 1:097424  10 2 1:101044  10 2 mM
d 1:871177  10 6 1:879996  10 6 [ ]
f 9:804391  10 1 9:789409  10 1 [ ]
f2 9:99401  10 1 9:993986  10 1 [ ]
fCaBj 2:847118  10 2 2:861794  10 2 [ ]
fCaBsl 1:692189  10 2 1:69833  10 2 [ ]
xKr 1:516232  10 2 1:896559  10 2 [ ]
RyRi 1:411382  10 7 1:43831  10 7 [ ]
RyRo 1:126209  10 6 1:149876  10 6 [ ]
RyRr 8:886338  10 1 8:888214  10 1 [ ]
xKs 3:549354  10 3 3:55636  10 3 [ ]
NaBj 3:796195 3:785209 mM
NaBsl 8:283308  10 1 8:259271  10 1 mM
Nai 1:007825  101 1:001989  101 mM
Naj 1:007931  101 1:00211  101 mM
Nasl 1:00781  101 1:001974  101 mM
xtof 3:584625  10 4 3:592405  10 4 [ ]
xtos 3:584727  10 4 3:592503  10 4 [ ]
ytof 9:999976  10 1 9:999976  10 1 [ ]
ytos 8:087629  10 1 8:161309  10 1 [ ]
Vm  84:13368  84:10546 mV
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Abstract
The use of experiments for studying cardiac arrhyth-
mias, the effect of drugs, or pathologies on cardiac elec-
trophysiology is very limited. This has made mathemat-
ical modeling and simulation of heart’s electrical activ-
ity a fundamental tool to understand cardiac behavior. In
this study several modifications were introduced to a re-
cently proposed human ventricular cell model. Four stimu-
lation protocols were applied to the original and improved
models of isolated cell, and a number of cellular arrhyth-
mic risk biomarkers were computed: steady-state action
potential (AP) and [Ca2+] transient properties, AP dura-
tion (APD) restitution curves, APD adaptation to abrupt
changes in heart rate, and intracellular [Ca2+] and [Na+]
rate dependence. Our modifications led to: a) further im-
proved AP triangulation (78.1 ms); b) APD rate adapta-
tion curves characterized by fast and slow time constants
within physiological ranges (10.1 s and 105.9 s); c) maxi-
mum S1S2 restitution slope in accordance with experimen-
tal data (SS1S2 = 1.0).
1. Introduction
Ventricular arrhythmias can have their origin in dis-
eases, genetic disorders, drug cardiotoxicity, and a num-
ber of other causes. Research in this field has identi-
fied a number of potential biomarkers of arrhythmic risk
related to cellular electrophysiological properties. How-
ever, performing experimental and clinical studies involv-
ing human hearts to quantify these biomarkers is very
difficult. On the other hand, animal hearts used for ex-
perimental studies may differ significantly from human
hearts. In addition, ventricular cardiac arrhythmias are
three-dimensional phenomena whereas experimental ob-
servations are still largely constrained to surface record-
ings. Under this circumstances, mathematical models of
myocardial cells and computer simulations of cardiac ac-
tivity in the human heart can overcome some of these prob-
lems.
Recently, a new model has been proposed by Grandi
et al. [1] (GR) that improves the response to frequency
changes and has a better performance against current
blocks with respect to the model proposed by ten Tusscher
and Panfilov [2] (TTP06). This article introduces several
modifications to the GR model by accounting for recent
experimental measurements of potassium currents [3] and
the introduction of fast and slow inactivation of L-type cal-
cium current [2]. The performance of the proposed model,
herein denoted by CRR, has been tested against the GR
and TTP06 models by applying four stimulation protocols
and computing twelve cellular arrhythmic risk biomarkers
following the methodology proposed in [4]. The results
show that the introduced modifications have brought most
biomarkers into the physiological range, and considerably
improved others with respect to the GR and TTP06 models
of AP.
2. Methods
2.1. Biomarkers of arrhythmic risk
Four stimulation protocols have been applied and twelve
cellular biomarkers of arrhythmic risk have been computed
as in [4]:
Steady-state AP and intracellular [Ca2+] concentration
properties. Systolic and diastolic [Ca2+]i levels under
steady-state pacing at frequencies of 0.5 and 1 Hz and
APD and AP Triangulation at 1 Hz have been calculated.
These biomarkers have been proposed as arrhythmic risk
biomarkers in the literature [5–7].
APD restitution (APDR) curves. APDR curves have
been obtained using the S1S2 and the dynamic restitution
protocols as in [4]. In both cases, the maximum slope,
suggested as a risk marker in the literature [8, 9], has been
computed.
APD rate adaptation to abrupt changes in cycle length
(CL). APD rate adaptation dynamics have been proposed
as a clinical marker in [10]. Dynamics have been fitted to
two exponentials with time constants τfast and τslow [11].
Rate dependence of steady-state [Na+]i and [Ca2+]i.
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Figure 1. ICaL characteristics in simulations and exper-
iments: a) Inactivation time constants; b) current density
versus voltage. Markers: experimental data.
The importance of [Na+]i and [Ca2+]i dynamics in ar-
rhythmogenesis has been reported [12, 13]. The systolic
values of both concentrations have been measured at dif-
ferent frequencies (0.25, 0.5, 1, 1.5, 2, 2.5 and 3 Hz) and
normalized to the level of the minimum frequency. The
maximum value has been computed and used as biomarker.
2.2. Modifications of the model
Two ionic currents have been reformulated and some
model parameters have been redefined in the GR model:
L-Type Calcium Current (ICaL ). The voltage-dependent
inactivation gate f has been replaced with the product of a
fast, f , and a slow, f2, inactivation gates as in [2]. Based
on available experimental data, the value of the opening
rate αf2 , associated with f2, has been modified to:
αf2 = 300 · e−
(Vm+25)
2
170 ,
where Vm denotes the transmembrane potential.
Figure 1a depicts τf and τf2 along with experimen-
tal data [2].The time constant (τd) of the activation gate
d has been replaced with the description given in [2].
The relative permeabilities of the L-type calcium chan-
nels have been adjusted to: pCa = 1.458 · 10−4 cm/s,
pK = 7.290 · 10−8 cm/s, pNa = 4.050 · 10−9 cm/s.
This new definition of ICaL is compared against experi-
mental data and the original definition of the GR model in
Figure 1b. Experimental data is from [14–16].
Inward Rectifier K Current (IK1). This current has been
re-adjusted based on experimental data from [3]. The re-
adjusted current is formulated as follows:
VEk = Vm − Ek
aK1 =
4.094
1.0 + e0.1217·(VEk−49.934)
bK1 =
15.720 · e0.0674·(VEk−3.257) + e0.0618·(VEk−594.31)
1.0 + e−0.1629·(VEk+14.207)
K1ss =
aK1
aK1 + bK1
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Figure 2. Maximum IK1 versus voltage and experimental
data. [K+]i = 138 mM and [K+]o = 4 mM . Blue dots:
experimental data.
IK1 = 0.5715 ·
√
[K+]o
5.4
·K1ss · VEk
where [K+]o denotes the extracellular K+ concentration,
and EK is the K+ reversal potential. Figure 2 shows the
modified IK1 compared against the experimental data from
[3] and IK1 from the GR model. Note that Figure 2b is a
zoom from Figure 2a.
INa,K: Na/K Pump Current. Maximal INa,K conductance
has been reduced by 45%.
[K+]i and GNa. A more physiological value of [K+]i
(138 mM ) has been used in the model. In this regard, in
order to get physiological values for the maximal upstroke
velocity, dV/dt, the maximum conductance of the sodium
current, GNa, has been reduced to 18.86 mS/µF .
2.3. Blocking Currents
We have also studied the behavior of the model under
total and partial block of potassium currents, comparing
the results against those reported in [17]:
IKs: To simulate the effect of 1 µM of HMR-1556, IKs
has been completely blocked.
IKr: To simulate the effect of 50 nM of dofetilide, IKr
has been completely blocked.
IK1: To simulate the effect of 10 µM of BaCl2, IK1 has
been blocked at 50%.
2.4. Numerical implementation and simu-
lation
Model differential equations were implemented in For-
tran. Cells were stimulated with square transmembrane
current pulses twice the diastolic threshold at CL = 1000
ms and 1-ms duration. Forward Euler integration with a
time step ∆t = 0.002 ms was used to integrate the sys-
tem of differential equations governing the cellular elec-
trical behavior. The Rush and Larsen integration scheme
was used to integrate the Hodgkin-Huxley type equations
for the gating variables of the various time-dependent cur-
rents.
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Biomarker TTP06 GR CRR Physiolo.
APD90 301.2 285.0 306.1 271-366
Triangulation 28.4 51.5 78.1 44-112
Sys [Ca2+]i 1 Hz 0.886 0.383 0.602 1.59-2.01
Sys [Ca2+]i 0.5 Hz 0.199 0.345 0.522 0.71-1.68
Dia [Ca2+]i 1 HZ 0.104 0.089 0.097 0.20-0.33
Dia [Ca2+]i 0.5 Hz 0.068 0.085 0.091 0.14-0.32
SmaxS1S2 1.3 0.2 1.0 0.79-4.25
SmaxDYN 1.0 1.1 0.9 —
τfast 13.3 — 10.1 —
τslow 124.8 56.3 105.9 70-110
Max. sys. [Ca2+]i 1157 178 147 130-170
Max. sys. [Na+]i 217 132 134 145
Table 1. Biomarkers of arrhythmic risk for the TTP06,
GR and CRR human models. Green color indicates within
physiological range. Blue color indicates out of physio-
logical range but better than previous models. Red color
indicates out of physiological range.
3. Results
3.1. Biomarkers of arrhythmic risk
Table 1 shows the computed biomarkers for the modi-
fied model, CRR. Results are compared against those ob-
tained with previous models (TTP06 and GR) and against
a variety of physiological data described in [4].
These results indicate that the GR model performs bet-
ter than the TTP06 model, with respect to the following
biomarkers: triangulation, systolic and diastolic [Ca2+]i
at 0.5 Hz and rate dependence of steady-state [Na+]i and
[Ca2+]i. However, according to other analyzed biomark-
ers, the GR model renders worse results than the TTP06
model. Particularly, in [18] two phases of APD rate adap-
tation curve were reported: a first phase with a rapid time
constant and a second phase with a slower time constant.
The GR model does not present this first phase. Also, the
S1S2 restitution curves of the TTP06 model (Figure 3c)
are in better agreement with experimental data.
For the CRR model, most of the twelve analyzed
biomarkers are within the physiological range or otherwise
closer to the physiological range as compared to GR and
TTP06 models, except for systolic and diastolic [Ca2+]i
levels at 0.5 Hz where TTP06 outperforms CRR.
3.2. Blocking Currents
Table 2 summarizes the effect of current block on the
different models. Results are given as percentage of vari-
ation of the APD value in control conditions. In those
cases where more than one current is blocked, the varia-
tion refers to the APD obtained when the first current is
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Figure 3. Biomarkers of arrhythmic risk from TTP06, GR
and CRR models: a) AP for CL = 1000 ms; b) APD rate
adaptation to abrupt changes in CL (From 1000 ms to 600
ms); c) S1S2 restitution protocol curve; d) Dynamic resti-
tution protocol curve; e) rate dependence of steady-state
[Na+]i; f) rate dependence of steady-state [Ca2+]i
blocked. Experimental values have been taken from [17].
4. Discussion and conclusions
This study introduces several modifications to the GR
model by accounting for recent experimental measure-
ments of potassium currents, and by reformulating the
L-type calcium current so as to introduce fast and slow
voltage-dependent inactivation. All the modifications have
been made with the aim of maintaining the advantages that
the GR model presents over previous models while im-
proving the performance on other electrophysiological as-
pects.
For the proposed CRR model, the introduction of fast
and slow ICaL inactivation has led to a more physiologi-
cal rate adaptation response as compared to the original
GR model. The other modifications have rendered most
biomarkers to be within the physiological range or other-
wise closer to the physiological range as compared to the
GR and TTP06 models, except for systolic and diastolic
[Ca2+]i levels at 0.5 Hz where TTP06 outperforms CRR.
These modifications, however, have altered the behavior of
the model against current blocks minimally.
The results of the analysis conducted in this study points
out the importance that calcium dynamics have over differ-
UniversidadZaragoza
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Current Ref. TT GR CRR Exper.
IKr 0% Control 74.9 0.7 0.6 < 2.8
IKr 0% Control 15.9 18.6 14.1 44±4
IKs 0% IKr B. — 1.4 0.8 9IKr 0%
IK1 50% Control 3.6 11.5 14.6 4.8±1.5
IKr 0% IKr B. 8.9 15.6 21.1 33IK1 50%
Table 2. Percentages of variation in the APD caused by
blocking different currents. Green color indicates within
physiological range. Blue color indicates out of physio-
logical range but better than previous models. Red color
indicate out of physiological range.
ent biomarkers. This suggests the need for continuing with
the development of more reliable calcium dynamic models
that allow improving the performance of whole cell AP
models.
Further developments of the proposed model will in-
clude conducting a sensitivity analysis of the studied
biomarkers to changes in model parameters as proposed in
[4], as well as testing the performance of the model under
pathological conditions such as hyperkalemia.
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Appendix C
Abbreviations
 ADP: Adenosine Diphosphate
 AP: Action Potential
 APD: Action Potential Duration
 APDR: Action Potential Duration Restitution
 ATP: Adenosine Triphosphate
 CI: Coupling Interval
 CL: Cycle Length
 CRLP: Model proposed in this work
 CV: Conduction Velocity
 CVD: Cardiovascular Disease
 DI: Diastolic Interval
 ECG: Electrocardiogram
 EGM: Electrogram
 ERP: Effective Refractory Period
 EU: European Union
 GPB: Grandi et al. (2010) model
 ODE: Ordinary Differential Equations
 PDE: Partial Differential Equations
 SCD: Sudden Cardiac Death
 TNNP04: ten Tusscher et al. (2004) model
 TP06: ten Tusscher and Panölov (2006) model
 VF: Ventricular Fibrilation
 VT: Ventricular Tachycardia
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